EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TUBA1B as a novel prognostic biomarker correlated with immunosuppressive tumor microenvironment and immunotherapy response

Juntao Qi, Mingming Zhou, Na Yang, Huiyun Ma, Min He, Gujie Wu, Chang Ge, Liuyin Jin, Lin Cheng, Wei Liao, Hefei Ren, Caiyun Lei

Frontiers in Pharmacology · 04.02.2025 · 16

DOI: 10.3389/fphar.2025.1517887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.02.2025. Verfasst von Juntao Qi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Rehabilitation Medicine Department, Hunan Aerospace Hospital, Hunan Normal University, Changsha, Hunan, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tubulin alpha 1b (TUBA1B) is a key microtubule protein essential for maintaining cellular structure and function. This protein contributes significantly to cytoskeletal formation and is implicated in various diseases. Despite its fundamental roles, TUBA1B’s impact on tumor prognosis and the tumor immune microenvironment across cancer types remains inadequately understood.

Methods

To elucidate TUBA1B’s role in cancer prognosis and immune response, we conducted a comprehensive analysis, integrating data from established databases such as The Cancer Genome Atlas, Genotype Tissue Expression, Cancer Cell Lineage Encyclopedia, Human Protein Atlas, Kaplan-Meier Plotter, cBioPortal, TIMER, and ImmuCellAI, along with a large-scale clinical study and immunotherapy cohort. We also conducted in vitro functional assays to assess TUBA1B’s functional role in tumor cells, allowing for a detailed examination of its relationship with cancer prognosis and immune modulation.

Results

Our findings indicate that TUBA1B expression is dysregulated across multiple cancers, correlating strongly with poor survival outcomes and advanced pathological stages. Functional enrichment analyses further revealed that TUBA1B regulates key cell cycle processes, driving tumor proliferation, migration, and invasion. It also influences immune functions within both the innate and adaptive immune systems, affecting immune-related signaling pathways. These insights underscore TUBA1B’s multifaceted role in cancer progression and immune response.

Conclusion

This study highlights TUBA1B’s potential as a human oncogene with substantial roles in tumorigenesis and immune regulation. Elevated TUBA1B levels are associated with an immunosuppressive tumor microenvironment, impacting cancer progression and treatment outcomes. Targeting TUBA1B may offer promising therapeutic avenues for enhancing cancer treatment, offering new perspectives for innovative anti-tumor strategies with high clinical impact.

Schlagwörter

Stichwörter der Autor:innen

TUBA1Banti-tumor strategiesbiomarkerprognosistumor microenvironment

Autor:innen und Institutionen

  • Rehabilitation Medicine Department, Hunan Aerospace Hospital, Hunan Normal University, Changsha, Hunan, China.
  • Research Center of Clinical Medicine, Shenzhen Hospital of Shanghai University of Traditional Chinese Medicine, Shenzhen, China.
  • Department of Critical Care Medicine, Chongqing University Affiliated Cancer Hospital, Chongqing, China.
  • Laboratory of Oncology and Immunology, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China.
  • Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China.
  • Shanghai Medical College, Fudan University, Shanghai, China.

Zitieren

APA

Qi, J., Zhou, M., Yang, N., Ma, H., He, M., Wu, G., Ge, C., Jin, L., Cheng, L., Liao, W., Ren, H., & Lei, C. (2025). TUBA1B as a novel prognostic biomarker correlated with immunosuppressive tumor microenvironment and immunotherapy response. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1517887

Vancouver

Qi J, Zhou M, Yang N, Ma H, He M, Wu G, et al. TUBA1B as a novel prognostic biomarker correlated with immunosuppressive tumor microenvironment and immunotherapy response. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1517887

BibTeX
@article{Qi2025,
  author = {Qi, Juntao and Zhou, Mingming and Yang, Na and Ma, Huiyun and He, Min and Wu, Gujie and Ge, Chang and Jin, Liuyin and Cheng, Lin and Liao, Wei and Ren, Hefei and Lei, Caiyun},
  title = {TUBA1B as a novel prognostic biomarker correlated with immunosuppressive tumor microenvironment and immunotherapy response},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1517887}
}
Kostenlos starten →